Eli Lilly’s experimental weight loss pill, orforglipron phase 3 clinical trial result update
Eli Lilly’s experimental once-daily pill, orforglipron, has shown promising Phase 3 trial results, helping over 3,000 adults lose an average…
Category: Research Insights
The Evolution of Obesity: Origins and Prevention
Early History and Evolution of Obesity Ancient Existence: Evidence of obesity dates back over 25,000 years, as depicted in Stone…
The Risky Rise of DIY Weight-Loss Drugs: Americans Turning to Unregulated Imports
As demand for weight-loss medications like Wegovy (semaglutide) and Zepbound (tirzepatide) skyrockets, a growing number of Americans are bypassing traditional healthcare systems and turning…
Diabesity: The Rising Challenge of Diabetes and Obesity and How Biocon is Taking the Lead
In the world of modern healthcare, there’s a new term that’s creating waves: Diabesity. Coined to capture the dual epidemic…
Retatrutide: The Next-Gen ‘Triple G’ Weight Loss Drug Shows Promising Results
Retatrutide is a promising experimental weight loss drug under development by Eli Lilly. Known as the “Triple G” drug, it…
The Most Obese Countries in the World: A 2024 WHO Report on Global Obesity Rates
In today’s world, obesity is more than just a health concern—it’s a global epidemic. According to the latest World Health…
Semaglutide in the ESSENCE Trial: A Breakthrough for Liver Disease Treatment?
Liver disease, especially metabolic dysfunction-associated steatohepatitis (MASH), has long been a silent threat, affecting millions of people globally. Often progressing…